Efficacy and Safety of an Orodispersible Vardenafil Formulation for the Treatment of Erectile Dysfunction in Elderly Men and Those with Underlying Conditions: An Integrated Analysis of Two Pivotal Trials
Men with erectile dysfunction (ED) are typically older and have one or more underlying cardiovascular conditions. To determine the efficacy and safety of a new orodispersible tablet (ODT) formulation of vardenafil for the treatment of ED, and whether age, or the presence of underlying conditions aff...
Gespeichert in:
| Veröffentlicht in: | Journal of sexual medicine 2011-01, Vol.8 (1), p.261-271 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 271 |
|---|---|
| container_issue | 1 |
| container_start_page | 261 |
| container_title | Journal of sexual medicine |
| container_volume | 8 |
| creator | Sperling, Herbert Gittelman, Marc Norenberg, Christiane Ulbrich, Ernst Ewald, Silke |
| description | Men with erectile dysfunction (ED) are typically older and have one or more underlying cardiovascular conditions.
To determine the efficacy and safety of a new orodispersible tablet (ODT) formulation of vardenafil for the treatment of ED, and whether age, or the presence of underlying conditions affects treatment outcomes.
This is an integrated analysis of data from two phase III, double‐blind, multicenter, randomized, parallel‐group, placebo‐controlled studies that compared 10 mg on‐demand vardenafil ODT with placebo in a general population of men with ED, stratified so that approximately 50% of patients were aged ≥65 years. Results were reported by age ( |
| doi_str_mv | 10.1111/j.1743-6109.2010.02005.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_822555200</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1743609515332379</els_id><sourcerecordid>822555200</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4655-c28865d527b922c4156a9697a0be0f011ee7ccc9c7373d3521268d452029f3483</originalsourceid><addsrcrecordid>eNqNUU1vEzEQXSEQLYW_gHzjtMHrjfcDiUOTpqWopRVJ26Pl2OPGYWMH22myv5E_hTfb5gpzGY_nvXmaeUmCMjzIYnxeDrJymKdFhusBwfEXE4zpYPcqOT40Xr-8cU2PknfeLzHOY5C3yRHBFS5zQo6TPxOltOCiRdxINOUKQousihW6cVZqvwbn9bwBdM-dBMOVbtC5datNw4O2BinrUFgAmjngYQUmdOyJAxF0JJ21Xm2M2CO1QZNGgmtadA1mrzdbWA9oq8MC3Zl9S5tHNLZG6o7iv6BTgy5NgEfHA8hY8ab12ncas61Ft_rJBt5Ecc0b_z55o2KCD8_5JLk7n8zG39Krm4vL8elVKoYFpakgVVVQSUk5rwkRw4wWvC7qkuM5YIWzDKAUQtSizMtc5pRkpKjkkBJMapUPq_wk-dTPXTv7ewM-sJX2ApqGG7AbzypCKI1wHJFVjxTOeu9AsbXTK-5almHWOcmWrDOJdYaxzkm2d5LtIvXjs8hmvgJ5IL5YFwFfe8A2Hrr978Hs-_S6e0V-2vO1D7A78Ln7xYq4OWUPPy5YNcpGP2_vH9g04kc9HuJpnzQ45oUGI0Dqzm0mrf73Vn8BHhfTYw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>822555200</pqid></control><display><type>article</type><title>Efficacy and Safety of an Orodispersible Vardenafil Formulation for the Treatment of Erectile Dysfunction in Elderly Men and Those with Underlying Conditions: An Integrated Analysis of Two Pivotal Trials</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Oxford Academic</source><creator>Sperling, Herbert ; Gittelman, Marc ; Norenberg, Christiane ; Ulbrich, Ernst ; Ewald, Silke</creator><creatorcontrib>Sperling, Herbert ; Gittelman, Marc ; Norenberg, Christiane ; Ulbrich, Ernst ; Ewald, Silke</creatorcontrib><description>Men with erectile dysfunction (ED) are typically older and have one or more underlying cardiovascular conditions.
To determine the efficacy and safety of a new orodispersible tablet (ODT) formulation of vardenafil for the treatment of ED, and whether age, or the presence of underlying conditions affects treatment outcomes.
This is an integrated analysis of data from two phase III, double‐blind, multicenter, randomized, parallel‐group, placebo‐controlled studies that compared 10 mg on‐demand vardenafil ODT with placebo in a general population of men with ED, stratified so that approximately 50% of patients were aged ≥65 years. Results were reported by age (<65 vs. ≥65 years) and presence/absence of diabetes, dyslipidemia, or hypertension.
Primary measures were the erectile function domain of the International Index of Erectile Function (IIEF‐EF) and Sexual Encounter Profile questions 2 (SEP2) and 3 (SEP3).
Of the 701 men randomized (51% aged ≥65 years), 686 were included in the intent‐to‐treat population (placebo, n = 334; vardenafil ODT, n = 352). Vardenafil ODT was significantly superior to placebo for all primary efficacy measures, regardless of age, baseline ED severity, or underlying condition (P < 0.0001 for vardenafil vs. placebo for each endpoint). IIEF‐EF scores and SEP2/3 success rates in older patients and men with underlying conditions were not significantly different to those of younger patients or men without underlying conditions. Adverse events (AEs) were mostly mild to moderate in severity, occurring with higher incidence in the vardenafil vs. placebo group. The most frequently reported drug‐related AEs in the vardenafil group were headache, flushing, nasal congestion, dizziness, and dyspepsia, consistent with the known safety profile of phosphodiesterase type 5 inhibitors.
Vardenafil ODT significantly improves erectile function in men with ED regardless of age, baseline ED severity, or underlying condition. Sperling H, Gittelman M, Norenberg C, Ulbrich E, and Ewald S. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: An integrated analysis of two pivotal trials. J Sex Med 2011;8:261–271.</description><identifier>ISSN: 1743-6095</identifier><identifier>EISSN: 1743-6109</identifier><identifier>DOI: 10.1111/j.1743-6109.2010.02005.x</identifier><identifier>PMID: 20807322</identifier><language>eng</language><publisher>Malden, USA: Elsevier Inc</publisher><subject>Age Factors ; Aged ; Biological Availability ; Comorbidity ; Diabetes Mellitus ; Diabetes Mellitus - epidemiology ; Dosage Forms ; Double-Blind Method ; Dyslipidemia ; Dyslipidemias - epidemiology ; Elderly ; Erectile Dysfunction ; Erectile Dysfunction - drug therapy ; Erectile Dysfunction - epidemiology ; Humans ; Hypertension ; Hypertension - epidemiology ; Imidazoles - administration & dosage ; Imidazoles - adverse effects ; Imidazoles - pharmacokinetics ; Male ; Orodispersible ; Phosphodiesterase 5 Inhibitors - administration & dosage ; Phosphodiesterase 5 Inhibitors - adverse effects ; Phosphodiesterase 5 Inhibitors - pharmacokinetics ; Phosphodiesterase Type 5 Inhibitor ; Piperazines - administration & dosage ; Piperazines - adverse effects ; Piperazines - pharmacokinetics ; Randomized Controlled Trials as Topic ; Sulfones - administration & dosage ; Sulfones - adverse effects ; Sulfones - pharmacokinetics ; Triazines - administration & dosage ; Triazines - adverse effects ; Triazines - pharmacokinetics ; Vardenafil ; Vardenafil Dihydrochloride</subject><ispartof>Journal of sexual medicine, 2011-01, Vol.8 (1), p.261-271</ispartof><rights>2011 International Society for Sexual Medicine</rights><rights>2010 International Society for Sexual Medicine</rights><rights>2010 International Society for Sexual Medicine.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4655-c28865d527b922c4156a9697a0be0f011ee7ccc9c7373d3521268d452029f3483</citedby><cites>FETCH-LOGICAL-c4655-c28865d527b922c4156a9697a0be0f011ee7ccc9c7373d3521268d452029f3483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1743-6109.2010.02005.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1743-6109.2010.02005.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20807322$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sperling, Herbert</creatorcontrib><creatorcontrib>Gittelman, Marc</creatorcontrib><creatorcontrib>Norenberg, Christiane</creatorcontrib><creatorcontrib>Ulbrich, Ernst</creatorcontrib><creatorcontrib>Ewald, Silke</creatorcontrib><title>Efficacy and Safety of an Orodispersible Vardenafil Formulation for the Treatment of Erectile Dysfunction in Elderly Men and Those with Underlying Conditions: An Integrated Analysis of Two Pivotal Trials</title><title>Journal of sexual medicine</title><addtitle>J Sex Med</addtitle><description>Men with erectile dysfunction (ED) are typically older and have one or more underlying cardiovascular conditions.
To determine the efficacy and safety of a new orodispersible tablet (ODT) formulation of vardenafil for the treatment of ED, and whether age, or the presence of underlying conditions affects treatment outcomes.
This is an integrated analysis of data from two phase III, double‐blind, multicenter, randomized, parallel‐group, placebo‐controlled studies that compared 10 mg on‐demand vardenafil ODT with placebo in a general population of men with ED, stratified so that approximately 50% of patients were aged ≥65 years. Results were reported by age (<65 vs. ≥65 years) and presence/absence of diabetes, dyslipidemia, or hypertension.
Primary measures were the erectile function domain of the International Index of Erectile Function (IIEF‐EF) and Sexual Encounter Profile questions 2 (SEP2) and 3 (SEP3).
Of the 701 men randomized (51% aged ≥65 years), 686 were included in the intent‐to‐treat population (placebo, n = 334; vardenafil ODT, n = 352). Vardenafil ODT was significantly superior to placebo for all primary efficacy measures, regardless of age, baseline ED severity, or underlying condition (P < 0.0001 for vardenafil vs. placebo for each endpoint). IIEF‐EF scores and SEP2/3 success rates in older patients and men with underlying conditions were not significantly different to those of younger patients or men without underlying conditions. Adverse events (AEs) were mostly mild to moderate in severity, occurring with higher incidence in the vardenafil vs. placebo group. The most frequently reported drug‐related AEs in the vardenafil group were headache, flushing, nasal congestion, dizziness, and dyspepsia, consistent with the known safety profile of phosphodiesterase type 5 inhibitors.
Vardenafil ODT significantly improves erectile function in men with ED regardless of age, baseline ED severity, or underlying condition. Sperling H, Gittelman M, Norenberg C, Ulbrich E, and Ewald S. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: An integrated analysis of two pivotal trials. J Sex Med 2011;8:261–271.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Biological Availability</subject><subject>Comorbidity</subject><subject>Diabetes Mellitus</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>Dosage Forms</subject><subject>Double-Blind Method</subject><subject>Dyslipidemia</subject><subject>Dyslipidemias - epidemiology</subject><subject>Elderly</subject><subject>Erectile Dysfunction</subject><subject>Erectile Dysfunction - drug therapy</subject><subject>Erectile Dysfunction - epidemiology</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - epidemiology</subject><subject>Imidazoles - administration & dosage</subject><subject>Imidazoles - adverse effects</subject><subject>Imidazoles - pharmacokinetics</subject><subject>Male</subject><subject>Orodispersible</subject><subject>Phosphodiesterase 5 Inhibitors - administration & dosage</subject><subject>Phosphodiesterase 5 Inhibitors - adverse effects</subject><subject>Phosphodiesterase 5 Inhibitors - pharmacokinetics</subject><subject>Phosphodiesterase Type 5 Inhibitor</subject><subject>Piperazines - administration & dosage</subject><subject>Piperazines - adverse effects</subject><subject>Piperazines - pharmacokinetics</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Sulfones - administration & dosage</subject><subject>Sulfones - adverse effects</subject><subject>Sulfones - pharmacokinetics</subject><subject>Triazines - administration & dosage</subject><subject>Triazines - adverse effects</subject><subject>Triazines - pharmacokinetics</subject><subject>Vardenafil</subject><subject>Vardenafil Dihydrochloride</subject><issn>1743-6095</issn><issn>1743-6109</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUU1vEzEQXSEQLYW_gHzjtMHrjfcDiUOTpqWopRVJ26Pl2OPGYWMH22myv5E_hTfb5gpzGY_nvXmaeUmCMjzIYnxeDrJymKdFhusBwfEXE4zpYPcqOT40Xr-8cU2PknfeLzHOY5C3yRHBFS5zQo6TPxOltOCiRdxINOUKQousihW6cVZqvwbn9bwBdM-dBMOVbtC5datNw4O2BinrUFgAmjngYQUmdOyJAxF0JJ21Xm2M2CO1QZNGgmtadA1mrzdbWA9oq8MC3Zl9S5tHNLZG6o7iv6BTgy5NgEfHA8hY8ab12ncas61Ft_rJBt5Ecc0b_z55o2KCD8_5JLk7n8zG39Krm4vL8elVKoYFpakgVVVQSUk5rwkRw4wWvC7qkuM5YIWzDKAUQtSizMtc5pRkpKjkkBJMapUPq_wk-dTPXTv7ewM-sJX2ApqGG7AbzypCKI1wHJFVjxTOeu9AsbXTK-5almHWOcmWrDOJdYaxzkm2d5LtIvXjs8hmvgJ5IL5YFwFfe8A2Hrr978Hs-_S6e0V-2vO1D7A78Ln7xYq4OWUPPy5YNcpGP2_vH9g04kc9HuJpnzQ45oUGI0Dqzm0mrf73Vn8BHhfTYw</recordid><startdate>201101</startdate><enddate>201101</enddate><creator>Sperling, Herbert</creator><creator>Gittelman, Marc</creator><creator>Norenberg, Christiane</creator><creator>Ulbrich, Ernst</creator><creator>Ewald, Silke</creator><general>Elsevier Inc</general><general>Blackwell Publishing Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201101</creationdate><title>Efficacy and Safety of an Orodispersible Vardenafil Formulation for the Treatment of Erectile Dysfunction in Elderly Men and Those with Underlying Conditions: An Integrated Analysis of Two Pivotal Trials</title><author>Sperling, Herbert ; Gittelman, Marc ; Norenberg, Christiane ; Ulbrich, Ernst ; Ewald, Silke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4655-c28865d527b922c4156a9697a0be0f011ee7ccc9c7373d3521268d452029f3483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Biological Availability</topic><topic>Comorbidity</topic><topic>Diabetes Mellitus</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>Dosage Forms</topic><topic>Double-Blind Method</topic><topic>Dyslipidemia</topic><topic>Dyslipidemias - epidemiology</topic><topic>Elderly</topic><topic>Erectile Dysfunction</topic><topic>Erectile Dysfunction - drug therapy</topic><topic>Erectile Dysfunction - epidemiology</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - epidemiology</topic><topic>Imidazoles - administration & dosage</topic><topic>Imidazoles - adverse effects</topic><topic>Imidazoles - pharmacokinetics</topic><topic>Male</topic><topic>Orodispersible</topic><topic>Phosphodiesterase 5 Inhibitors - administration & dosage</topic><topic>Phosphodiesterase 5 Inhibitors - adverse effects</topic><topic>Phosphodiesterase 5 Inhibitors - pharmacokinetics</topic><topic>Phosphodiesterase Type 5 Inhibitor</topic><topic>Piperazines - administration & dosage</topic><topic>Piperazines - adverse effects</topic><topic>Piperazines - pharmacokinetics</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Sulfones - administration & dosage</topic><topic>Sulfones - adverse effects</topic><topic>Sulfones - pharmacokinetics</topic><topic>Triazines - administration & dosage</topic><topic>Triazines - adverse effects</topic><topic>Triazines - pharmacokinetics</topic><topic>Vardenafil</topic><topic>Vardenafil Dihydrochloride</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sperling, Herbert</creatorcontrib><creatorcontrib>Gittelman, Marc</creatorcontrib><creatorcontrib>Norenberg, Christiane</creatorcontrib><creatorcontrib>Ulbrich, Ernst</creatorcontrib><creatorcontrib>Ewald, Silke</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of sexual medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sperling, Herbert</au><au>Gittelman, Marc</au><au>Norenberg, Christiane</au><au>Ulbrich, Ernst</au><au>Ewald, Silke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of an Orodispersible Vardenafil Formulation for the Treatment of Erectile Dysfunction in Elderly Men and Those with Underlying Conditions: An Integrated Analysis of Two Pivotal Trials</atitle><jtitle>Journal of sexual medicine</jtitle><addtitle>J Sex Med</addtitle><date>2011-01</date><risdate>2011</risdate><volume>8</volume><issue>1</issue><spage>261</spage><epage>271</epage><pages>261-271</pages><issn>1743-6095</issn><eissn>1743-6109</eissn><abstract>Men with erectile dysfunction (ED) are typically older and have one or more underlying cardiovascular conditions.
To determine the efficacy and safety of a new orodispersible tablet (ODT) formulation of vardenafil for the treatment of ED, and whether age, or the presence of underlying conditions affects treatment outcomes.
This is an integrated analysis of data from two phase III, double‐blind, multicenter, randomized, parallel‐group, placebo‐controlled studies that compared 10 mg on‐demand vardenafil ODT with placebo in a general population of men with ED, stratified so that approximately 50% of patients were aged ≥65 years. Results were reported by age (<65 vs. ≥65 years) and presence/absence of diabetes, dyslipidemia, or hypertension.
Primary measures were the erectile function domain of the International Index of Erectile Function (IIEF‐EF) and Sexual Encounter Profile questions 2 (SEP2) and 3 (SEP3).
Of the 701 men randomized (51% aged ≥65 years), 686 were included in the intent‐to‐treat population (placebo, n = 334; vardenafil ODT, n = 352). Vardenafil ODT was significantly superior to placebo for all primary efficacy measures, regardless of age, baseline ED severity, or underlying condition (P < 0.0001 for vardenafil vs. placebo for each endpoint). IIEF‐EF scores and SEP2/3 success rates in older patients and men with underlying conditions were not significantly different to those of younger patients or men without underlying conditions. Adverse events (AEs) were mostly mild to moderate in severity, occurring with higher incidence in the vardenafil vs. placebo group. The most frequently reported drug‐related AEs in the vardenafil group were headache, flushing, nasal congestion, dizziness, and dyspepsia, consistent with the known safety profile of phosphodiesterase type 5 inhibitors.
Vardenafil ODT significantly improves erectile function in men with ED regardless of age, baseline ED severity, or underlying condition. Sperling H, Gittelman M, Norenberg C, Ulbrich E, and Ewald S. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: An integrated analysis of two pivotal trials. J Sex Med 2011;8:261–271.</abstract><cop>Malden, USA</cop><pub>Elsevier Inc</pub><pmid>20807322</pmid><doi>10.1111/j.1743-6109.2010.02005.x</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1743-6095 |
| ispartof | Journal of sexual medicine, 2011-01, Vol.8 (1), p.261-271 |
| issn | 1743-6095 1743-6109 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_822555200 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Oxford Academic |
| subjects | Age Factors Aged Biological Availability Comorbidity Diabetes Mellitus Diabetes Mellitus - epidemiology Dosage Forms Double-Blind Method Dyslipidemia Dyslipidemias - epidemiology Elderly Erectile Dysfunction Erectile Dysfunction - drug therapy Erectile Dysfunction - epidemiology Humans Hypertension Hypertension - epidemiology Imidazoles - administration & dosage Imidazoles - adverse effects Imidazoles - pharmacokinetics Male Orodispersible Phosphodiesterase 5 Inhibitors - administration & dosage Phosphodiesterase 5 Inhibitors - adverse effects Phosphodiesterase 5 Inhibitors - pharmacokinetics Phosphodiesterase Type 5 Inhibitor Piperazines - administration & dosage Piperazines - adverse effects Piperazines - pharmacokinetics Randomized Controlled Trials as Topic Sulfones - administration & dosage Sulfones - adverse effects Sulfones - pharmacokinetics Triazines - administration & dosage Triazines - adverse effects Triazines - pharmacokinetics Vardenafil Vardenafil Dihydrochloride |
| title | Efficacy and Safety of an Orodispersible Vardenafil Formulation for the Treatment of Erectile Dysfunction in Elderly Men and Those with Underlying Conditions: An Integrated Analysis of Two Pivotal Trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T17%3A54%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20an%20Orodispersible%20Vardenafil%20Formulation%20for%20the%20Treatment%20of%20Erectile%20Dysfunction%20in%20Elderly%20Men%20and%20Those%20with%20Underlying%20Conditions:%20An%20Integrated%20Analysis%20of%20Two%20Pivotal%20Trials&rft.jtitle=Journal%20of%20sexual%20medicine&rft.au=Sperling,%20Herbert&rft.date=2011-01&rft.volume=8&rft.issue=1&rft.spage=261&rft.epage=271&rft.pages=261-271&rft.issn=1743-6095&rft.eissn=1743-6109&rft_id=info:doi/10.1111/j.1743-6109.2010.02005.x&rft_dat=%3Cproquest_cross%3E822555200%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=822555200&rft_id=info:pmid/20807322&rft_els_id=S1743609515332379&rfr_iscdi=true |